Specialized Program Of Research Excellence (SPORE) in Leukemia.

白血病专业卓越研究计划 (SPORE)。

• 批准号: 9756314
• 负责人: Daniel C Link
• 金额: $ 211.76万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-03 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9756314
• 关键词: Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Acute T Cell Leukemia; Allogenic; Animal Model; Antibody Therapy; Basic Science; Biometry; Bispecific Antibodies; CD3 Antigens; CXCR4 gene; Cancer Research Project; Clinical; Clinical Trials; Collaborations; Data; Decitabine; Development; Disabled Persons; Dysmyelopoietic Syndromes; Female; Genomics; Goals; Grant Review; Hematopoiesis; Immunology; Immunotherapy; Infrastructure; Institution; Joints; Laboratories; Memory; Mentors; Minority; Molecular; Molecular Profiling; Multi-Institutional Clinical Trial; Mutate; Mutation; Natural Killer Cells; Nelarabine; Oral; Pathway interactions; Patients; Program Reviews; Property; RNA Splicing; Refractory; Relapse; Research; Research Personnel; Research Project Grants; Resistance; Resources; Salvage Therapy; Signal Transduction; Specialized Program of Research Excellence; TP53 gene; Testing; Therapeutic; Therapeutic Trials; Training; Training Programs; Translational Research; Universities; Washington; acute T-cell lymphoblastic leukemia cell; antibody conjugate; base; cancer genomics; career; conditioning; cytokine; first-in-human; fundamental research; hematopoietic cell transplantation; inhibitor/antagonist; innovation; leukemia; leukemia treatment; meetings; mutant; novel; novel marker; novel therapeutics; peer; pre-clinical; preclinical study; programs; recruit; research and development; response; targeted agent; targeted treatment; translational cancer research

ABSTRACT The Washington University SPORE in Leukemia is a highly dynamic translational cancer research program that focuses specifically on leukemias and myelodysplastic syndromes (MDS). We have assembled an outstanding group of investigators with complementary expertise in basic and clinical leukemia research. In this SPORE, we leverage expertise in cancer genomics, immunology, and hematopoiesis to develop innovative translational research in leukemia. Our long-term goal is to develop novel biomarkers and treatments for leukemias and myelodysplastic syndromes and to develop and promote innovative translational leukemia research. To achieve these goals, the following specific aims are proposed. Aim 1. We will exploit institutional expertise in cancer genomics, immunology, and hematopoiesis to develop novel biomarkers and treatments for leukemias and myelodysplastic syndromes. Basic research at WUSM has led to the development of the following five translational research projects, all featuring innovative investigator-initiated therapeutic trials for leukemias or MDS. · Project 1. Molecular determinants of decitabine responsiveness · Project 2. Targeted therapies for T cell acute lymphoblastic leukemia (T-ALL) · Project 3. Novel therapies for splicesome-mutant MDS · Project 4. Bi-specific antibody-based therapies for AML · Project 5. Memory-like NK cell augmented hematopoietic cell transplantation for AML Aim 2. We will enhance the infrastructure that supports translational leukemia research. This SPORE will support the following Shared Research Resources: 1) Core A. Biospecimen Processing; 2) Core B. Biostatistics; and 3) Core C. Administration. Aim 3. We will recruit and train new investigators in translational research. This SPORE will support a Career Enhancement Program (CEP) to recruit and mentor new investigators in translational leukemia research. The SPORE has established a successful minority post-baccalaureate training program. The SPORE also will support a Developmental Research Program (DRP) to support innovative translational concepts. Aim 4. We will facilitate inter-SPORE collaboration. Four of the SPORE projects include multi-institutional clinical trials, including three at other Leukemia SPORE institutions. We have established CEP educational exchange and grant review programs with peer Leukemia SPORE institutions. We will continue to organize and participate in joint meetings of Leukemia SPOREs at MD Anderson and Harvard.

抽象的 华盛顿大学白血病孢子是一项高度动态的转化癌研究计划， 专门针对白血病和骨髓增生综合征（MDS）。我们组装了一个杰出的 具有基础和临床白血病研究专业知识的研究人员小组。在这个孢子中，我们 利用癌症基因组学，免疫学和造血的专业知识来发展创新的翻译 白血病研究。我们的长期目标是为白血病和 骨髓增生性综合征，并开发和促进创新的翻译白血病研究。实现 这些目标是提出以下特定目标。 目标1。我们将利用癌症基因组学，免疫学和造血的机构专业知识 开发了白血病和骨髓增生综合征的新型生物标志物和治疗方法。基础研究 在WUSM导致了以下五个翻译研究项目的开发，所有这些项目都具有创新性 研究人员发射的白血病或MDS的治疗试验。 项目1。剪接响应能力的分子决定剂 项目2。针对T细胞急性淋巴细胞白血病（T-ALL）的靶向疗法 项目3。新型固定毒物MDS的新疗法 项目4。基于双特异性抗体的AML疗法 ·项目5。记忆状的NK细胞增强AML的造血细胞移植 目标2。我们将增强支持翻译白血病研究的基础设施。这个孢子 将支持以下共享的研究资源：1）核心A. Bispecececemen处理； 2）核心B。 生物统计学； 3）核心C.管理。 目标3。我们将招募和培训新的调查员在翻译研究中。这个孢子将支持 一项职业增强计划（CEP），旨在招募和指导转化白血病的新调查员 研究。孢子已经建立了一项成功的少数族裔后洞穴后培训计划。孢子 还将支持开发研究计划（DRP）以支持创新的翻译概念。 AIM 4。我们将支持跨间的合作。四个孢子项目包括多机构 临床试验，包括其他白血病孢子机构的三个。我们已经建立了CEP教育 与同伴白血病孢子机构进行交流和授予审查计划。我们将继续组织和 参加马里兰州安德森和哈佛大学中的白血病孢子的联合会议。